Chen Xuemin, Crawford McKenna C, Xiong Ying, Shaik Anver Basha, Suazo Kiall F, Bauer Ludwig G, Penikalapati Manini S, Williams Joycelyn H, Huber Kilian V M, Andressen Thorkell, Swenson Rolf E, Meier Jordan L
Chemical Biology Laboratory, National Cancer Institute, Frederick, Maryland 21702, United States.
Chemistry and Synthesis Center, National Heart Lung and Blood Institute, Rockville, Maryland 20850, United States.
JACS Au. 2024 Jul 29;4(8):3094-3103. doi: 10.1021/jacsau.4c00442. eCollection 2024 Aug 26.
The transcriptional coactivators EP300 and CREBBP are critical regulators of gene expression that share high sequence identity but exhibit nonredundant functions in basal and pathological contexts. Here, we report the development of a bifunctional small molecule, MC-1, capable of selectively degrading EP300 over CREBBP. Using a potent aminopyridine-based inhibitor of the EP300/CREBBP catalytic domain in combination with a VHL ligand, we demonstrate that MC-1 preferentially degrades EP300 in a proteasome-dependent manner. Mechanistic studies reveal that selective degradation cannot be predicted solely by target engagement or ternary complex formation, suggesting additional factors govern paralogue-specific degradation. MC-1 inhibits cell proliferation in a subset of cancer cell lines and provides a new tool to investigate the noncatalytic functions of EP300 and CREBBP. Our findings expand the repertoire of EP300/CREBBP-targeting chemical probes and offer insights into the determinants of selective degradation of highly homologous proteins.
转录共激活因子EP300和CREBBP是基因表达的关键调节因子,它们具有高度的序列同一性,但在基础和病理情况下表现出非冗余功能。在此,我们报告了一种双功能小分子MC-1的开发,它能够选择性地降解EP300而不是CREBBP。通过将一种基于氨基吡啶的强效EP300/CREBBP催化结构域抑制剂与一种VHL配体结合使用,我们证明MC-1以蛋白酶体依赖性方式优先降解EP300。机制研究表明,选择性降解不能仅通过靶点结合或三元复合物形成来预测,这表明还有其他因素控制着旁系同源物特异性降解。MC-1在一部分癌细胞系中抑制细胞增殖,并为研究EP300和CREBBP的非催化功能提供了一种新工具。我们的发现扩展了靶向EP300/CREBBP的化学探针库,并为高度同源蛋白质选择性降解的决定因素提供了见解。